287,456 Shares in Soleno Therapeutics, Inc. $SLNO Acquired by Aberdeen Group plc

Key Points

• Neurocrine acquisition: Neurocrine agreed to acquire Soleno for $53.00 per share (about $2.9 billion), giving shareholders an immediate cash premium and a clear near‑term exit.
• Aberdeen stake: Aberdeen Group plc initiated a new position of 287,456 shares (~$13.3M), representing about 0.54% of Soleno amid overall institutional ownership of 97.42%.
• Risks and headwinds: Soleno withdrew its EU marketing application for VYKAT™ XR, is facing securities class‑action solicitations tied to 2025 trial setbacks, and multiple analysts have cut targets or downgraded the stock, which could limit international upside and pressure deal economics.

Aberdeen Group plc bought a new position in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 287,456 shares of the company's stock, valued at approximately $13,309,000. Aberdeen Group plc owned about 0.54% of Soleno Therapeutics at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Raymond James Financial Inc. bought a new stake in Soleno Therapeutics in the 2nd quarter worth approximately $25,000. Danske Bank A S bought a new stake in Soleno Therapeutics in the 3rd quarter worth approximately $27,000. Aster Capital Management DIFC Ltd bought a new position in shares of Soleno Therapeutics during the third quarter valued at about $37,000. Quarry LP bought a new position in shares of Soleno Therapeutics during the third quarter valued at about $47,000. Finally, Quantbot Technologies LP bought a new position in shares of Soleno Therapeutics during the third quarter valued at about $67,000. Institutional investors own 97.42% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on SLNO shares. Cantor Fitzgerald cut Soleno Therapeutics from an "overweight" rating to a "hold" rating and reduced their price objective for the company from $123.00 to $53.00 in a research note on Monday. HC Wainwright reduced their price objective on Soleno Therapeutics from $120.00 to $100.00 and set a "buy" rating on the stock in a research note on Wednesday, March 4th. Zacks Research cut Soleno Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, February 3rd. Oppenheimer reduced their price objective on Soleno Therapeutics from $110.00 to $80.00 and set an "outperform" rating on the stock in a research note on Wednesday, March 18th. Finally, TD Cowen reaffirmed a "hold" rating and set a $53.00 price objective (down from $85.00) on shares of Soleno Therapeutics in a research note on Tuesday. Seven investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Soleno Therapeutics currently has an average rating of "Hold" and a consensus price target of $93.90.

Key Soleno Therapeutics News

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Neurocrine agreed to acquire Soleno for $53.00 per share in cash (about $2.9B), giving SLNO shareholders an immediate cash premium and a clear near‑term exit/liquidity event. Read More.
• Neutral Sentiment: Some research shops have set conservative near‑term views (reaffirmations / “peer perform” ratings) as the deal closes and integration risk becomes the focus; these are neutral for deal economics but can mute momentum. Read More.
• Negative Sentiment: Soleno voluntarily withdrew its European marketing application for VYKAT™ XR, citing the acquirer’s plan to sharpen focus on the U.S. market — this reduces near‑term international upside and could lower future revenue projections for the combined company. Read More.
• Negative Sentiment: Dozens of law firms have filed or are soliciting plaintiffs in securities class actions tied to Soleno’s 2025 DCCR/VYKAT XR trial/launch setbacks; litigation risk could create damages exposure, distraction and potential deal complications. Read More.
• Negative Sentiment: Multiple firms are investigating whether the $53/share deal is fair to public shareholders and several analysts have downgraded or cut targets — these actions can pressure the stock and may prompt negotiation or litigation over price. Read More.

Soleno Therapeutics Trading Up 0.2%

NASDAQ:SLNO opened at $52.35 on Wednesday. The company has a fifty day moving average of $38.17 and a 200 day moving average of $47.80. Soleno Therapeutics, Inc. has a 52 week low of $29.43 and a 52 week high of $90.32. The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $2.70 billion, a P/E ratio of 227.62 and a beta of -2.81.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, beating analysts' consensus estimates of $0.64 by $0.16. The firm had revenue of $91.73 million for the quarter, compared to the consensus estimate of $88.55 million. On average, research analysts predict that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current year.

Soleno Therapeutics Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company's scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company's lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.

Want to see what other hedge funds are holding SLNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.